Real-world (RW) outcomes of second-line (2L) small cell lung cancer (SCLC) patients treated with lurbinectedin

被引：4
|
作者：
Estrin, A. [1 ]
Wang, X. [2 ]
Boccuti, A. [3 ]
Prince, P. [1 ]
Gautam, N. [1 ]
Rengarajan, B. [3 ]
Li, W. [2 ]
Lu, T. [3 ]
Cao, Y. [2 ]
Naveh, N. [2 ]
D'Agostino, R. [4 ]
Ben-Joseph, R. [3 ]
Ganti, A. K. [5 ]
机构：
[1] Aetion Inc, Sci, New York, NY USA
[2] Jazz Pharmaceut, Med Affairs, Philadelphia, PA USA
[3] Jazz Pharmaceut, Med Affairs, Palo Alto, CA USA
[4] Wake Forest Univ Sch Med, Biostat & Data Sci, Winston Salem, NC USA
[5] Univ Nebraska Med Ctr, VA Nebraska Western Iowa Hlth Care Syst, Nebraska Med Ctr, Omaha, NE USA
来源：
ANNALS OF ONCOLOGY | 2022年 / 33卷 / 07期
关键词：
D O I：
10.1016/j.annonc.2022.07.1633
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1539P
引用
收藏
页码：S1250 / S1250
页数：1
相关论文
共 50 条
  • [31] Zweitlinientherapie des kleinzelligen Lungenkarzinoms (SCLC)Second-line therapy for small cell lung cancer (SCLC)
    F. Griesinger
    T. Overbeck
    N. Niederle
    Der Onkologe, 2005, 11 (7): : 730 - 740
  • [32] Considerations for selecting second-line treatment in patients with progressive small cell lung cancer and the use of Lurbinectedin in this setting
    Badin, Firas
    CANCER TREATMENT AND RESEARCH COMMUNICATIONS, 2024, 39
  • [33] Real-world outcomes in patients with KRAS p.G12C mutant advanced non-small cell lung cancer (aNSCLC) treated with docetaxel in second-line or beyond (2L+).
    Hsu, Hil
    Younan, Diana
    Suri, Gaurav
    Chia, Victoria M.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [34] HEALTHCARE COSTS AMONG REAL-WORLD PATIENTS WITH RECURRENT OR METASTATIC CERVICAL CANCER (R/MCC) RECEIVING SECOND-LINE (2L) TREATMENT
    Inocencio, T.
    Wu, N.
    Ge, W.
    Gleeson, M.
    Monk, B. J.
    VALUE IN HEALTH, 2022, 25 (07) : S412 - S413
  • [35] Phase 2 Basket Trial of Lurbinectedin in Second-line SCLC: Characteristics and Outcomes in Treatment Responders
    Subbiah, V.
    Paz-Ares, L.
    Besse, B.
    Moreno, V.
    Peters, S.
    Sala, M. A.
    Lopez-Vilarino, J. A.
    Fernandez, C.
    Kahatt, C.
    Zeaiter, A.
    Zaman, K.
    Delord, J. -P.
    Martinez, M.
    Anton, A.
    Awada, A.
    Kristeleit, R.
    Olmedo, M. E.
    Rubio, M. J.
    Sarantopoulos, J.
    D'Arcangelo, M.
    Santoro, A.
    Trigo, Jose M.
    Sands, J.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (01) : S18 - S19
  • [36] Topotecan in a Real-World Small-Cell Lung Cancer Cohort: Prognostic Biomarkers Improve Selection of Patients for Second-Line Treatment
    Lambrecht, Laura
    Arnold, Paola
    Behr, Juergen
    Mertsch, Pontus
    Tufman, Amanda
    Kauffmann-Guerrero, Diego
    DIAGNOSTICS, 2024, 14 (14)
  • [37] Real-world study of lazertinib as second-line or greater treatment in advanced non-small cell lung cancer
    Lim, Jeong Uk
    Kim, Kyuhwan
    Kim, Kyu Yean
    Kang, Hye Seon
    Shin, Ah. Young
    Yeo, Chang Dong
    Kim, Sung Kyoung
    Park, Chan Kwon
    Lee, Sang Haak
    Kim, Seung Joon
    THORACIC CANCER, 2024, 15 (19) : 1513 - 1521
  • [38] Review of real-world experience with lurbinectedin in relapsed/refractory small cell lung cancer
    Wasifuddin, Mustafa
    Ilerhunmwuwa, Nosakhare Paul
    Becerra, Henry
    Hakobyan, Narek
    Wasifuddin, Saad
    Al Asadi, Hayder
    Wang, Jen Chin
    JOURNAL OF CHEMOTHERAPY, 2024, 36 (07) : 587 - 592
  • [39] Characterization of Real-World Use of Lurbinectedin in Adult Small Cell Lung Cancer Patients in the United States
    Wang, X.
    Rengarajan, B.
    Li, W.
    Prince, P.
    Paone, J.
    Rahai, N.
    Boccuti, A.
    Baratta, C.
    Lu, T.
    Cao, Y.
    Ganti, A. K.
    D'Agostino, R., Jr.
    Ben-Joseph, R.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S553 - S554
  • [40] Cost of adverse events (AEs) with second-line (2L) immuno-oncology agents (IO) and chemotherapy (CHEMO) in advanced non-small cell lung cancer (aNSCLC) in the real-world
    Wang, C. K.
    Gupte-Singh, K.
    Belli, A. J.
    Lane, D. C.
    Lakshmanan, A.
    Norden, A. D.
    ANNALS OF ONCOLOGY, 2019, 30
12345